Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms

Archives of Toxicology

Volumn 89, Issue 11, 2015, Pages 2089-2103

  Bitter, Andreas ^a   Rümmele, Petra ^b   Klein, Kathrin ^a   Kandel, Benjamin A ^a   Rieger, Jessica K ^a   Nüssler, Andreas K ^c   Zanger, Ulrich M ^a   Trauner, Michael ^d   Schwab, Matthias ^a,e   Burk, Oliver ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Hepatocyte; Lipogenesis; Non alcoholic steatohepatitis; Nuclear receptors; Pregnane X receptor; Sterol regulatory element binding protein 1

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; PREGNANE X RECEPTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL; AKR1B10 PROTEIN, HUMAN; ALDEHYDE REDUCTASE; LIGAND; STEROID RECEPTOR;

ARTICLE; CONTROLLED STUDY; FATTY LIVER; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; GENETICS; HEPG2 CELL LINE; METABOLISM; PATHOLOGY; UPREGULATION;

ACETYL-COA CARBOXYLASE; ALDEHYDE REDUCTASE; FATTY LIVER; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIGANDS; LIPOGENESIS; RECEPTORS, STEROID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIGLYCERIDES; UP-REGULATION;

EID: 84947606505     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1348-x     Document Type: Article

References (47)

1. Abdelmalek MF, Diehl AM (2007) Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am 91:1125–1149
2. Amemiya-Kudo M, Shimano H, Hasty AH et al (2002) Transcriptional activities of nuclear SREBP-1a, −1c, and −2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43:1220–1235
3. Anderson N, Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60:311–357
4. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37:911–917
5. Brunt EM, Janney CG, Di Bisceglie AM et al (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94:2467–2474
6. Burk O, Tegude H, Koch I et al (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:24280–24288
7. Cheung O, Puri P, Eicken C et al (2008) Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology 48:1810–1820
8. Cui JY, Gunewardena SS, Rockwell CE, Klaassen CD (2010) ChIPing the cistrome of PXR in mouse liver. Nucleic Acids Res 38:7943–7963
9. Dai G, He L, Bu P, Wan YJ (2008) Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 47:1277–1287
10. Dif N, Euthine V, Gonnet E et al (2006) Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs. Biochem J 400:179–188
11. Donnelly KL, Smith CI, Schwarzenberg SJ et al (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343–1351
12. Farese RV, Walther TC (2009) Lipid droplets finally get a little R-E-S-P-E-C-T. Cell 139:855–860
13. Fernández-Alvarez A, Tur G, López-Rodas G, Casado M (2008) Reciprocal regulation of the human sterol regulatory element binding protein (SREBP)-1a promoter by Sp1 and EGR-1 transcription factors. FEBS Lett 582:177–184
14. Geick A, Eichelbaum M, Burk O (2001) Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J Biol Chem 276:14581–14587
15. George J, Liddle C (2008) Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol Pharm 5:49–59
16. Ghose R, Omoluabi O, Gandhi A et al (2011) Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci 89:57–64
17. Hawkins JL, Robbins MD, Warren LC et al (2008) Pharmacologic inhibition of site 1 protease activity inhibits sterol regulatory element-binding protein processing and reduces lipogenic enzyme gene expression and lipid synthesis in cultured cells and experimental animals. J Pharmacol Exp Ther 326:801–808
18. He J, Gao J, Xu M et al (2013) PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes 62:1876–1887
19. Hoffart E, Ghebreghiorghis L, Nussler AK et al (2012) Effects of atorvastatin metabolites on induction of drug-metabolizing enzymes and membrane transporters through human pregnane X receptor. Br J Pharmacol 165:1595–1608
20. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125–1131
21. Joshi A, Rajput S, Wang C et al (2010) Murine aldo–keto reductase family 1 subfamily B: identification of AKR1B8 as an ortholog of human AKR1B10. Biol Chem 391:1371–1378
22. Khogali AM, Chazan BI, Metcalf VJ, Ramsay JH (1974) Hyperlipidaemia as a complication of rifampicin treatment. Tubercle 55:231–233
23. Kodama S, Negishi M (2013) PXR cross-talks with internal and external signals in physiological and pathophysiological responses. Drug Metab Rev 45:300–310
24. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ (2014) Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146:726–735
25. Li ZZ, Berk M, McIntyre TM, Feldstein AE (2009) Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 284:5637–5644
26. Ma J, Yan R, Zu X et al (2008) Aldo–keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem 283:3418–3423
27. Moreau A, Téruel C, Beylot M et al (2009) A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 49:2068–2079
28. Nakamura K, Moore R, Negishi M, Sueyoshi T (2007) Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J Biol Chem 282:9768–9776
29. Nies AT, Koepsell H, Winter S et al (2009) Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology 50:1227–1240
30. Nussler AK, Nussler NC, Merk V et al (2009) The holy grail of hepatocyte culturing and therapeutic use. In: Santin M (ed) Strategies in regenerative medicine. Springer, New York, pp 283–320
31. Pascussi JM, Robert A, Nguyen M et al (2005) Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest 115:177–186
32. Reed BD, Charos AE, Szekely AM et al (2008) Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. PLoS Genet 4:e1000133
33. Rysä J, Buler M, Savolainen MJ et al (2013) Pregnane X receptor agonists impair postprandial glucose tolerance. Clin Pharmacol Ther 93:556–563
34. Sanyal AJ (2005) Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2:46–53
35. Shimomura I, Shimano H, Horton JD et al (1997) Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells. J Clin Invest 99:838–845
36. Sookoian S, Castaño GO, Burgueño AL et al (2010) The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 20:1–8
37. Spruiell K, Richardson RM, Cullen JM et al (2014) Role of pregnane X receptor in obesity and glucose homeostasis in male mice. J Biol Chem 289:3244–3261
38. Starmann J, Fälth M, Spindelböck W et al (2012) Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. PLoS One 7:e46584
39. Sundqvist A, Bengoechea-Alonso MT, Ye X et al (2005) Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7). Cell Metab 1:379–391
40. Takagi S, Nakajima M, Mohri T, Yokoi T (2008) Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem 283:9674–9680
41. Tolson AH, Wang H (2010) Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Adv Drug Deliv Rev 62:1238–1249
42. Trauner M, Halilbasic E (2011) Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 140:1120–1125
43. Tsuzura H, Genda T, Sato S et al (2014) Expression of aldo–keto reductase family 1 member B10 in the early stages of human hepatocarcinogenesis. Int J Mol Sci 15:6556–6568
44. Wagner M, Zollner G, Trauner M (2011) Nuclear receptors in liver disease. Hepatology 53:1023–1034
45. Wang C, Yan R, Luo D et al (2009) Aldo–keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem 284:26742–26748
46. Zhou J, Zhai Y, Mu Y et al (2006) A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J Biol Chem 281:15013–15020
47. Zhou C, Poulton EJ, Grün F et al (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220–229